1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
insider
insider
Articles 

DAFNA Capital Management LLC Buys WAVE Life Sciences, Alder BioPharmaceuticals Inc, Blueprint Medicines Corp, Sells Loxo Oncology Inc, NxStage Medical Inc, argenx SE

Los Angeles, CA, based Investment company DAFNA Capital Management LLC buys WAVE Life Sciences, Alder BioPharmaceuticals Inc, Blueprint Medicines Corp, Mersana Therapeutics Inc, Kadmon Holdings Inc, Cytokinetics Inc, Genocea Biosciences Inc, Corbus Pharmaceuticals Holdings Inc, Xenon Pharmaceuticals Inc, Inogen Inc, Dermira Inc, Savara Inc, Zafgen Inc, Ardelyx Inc, Radius Health Inc, Aileron Therapeutics Inc, Minerva Neurosciences Inc, Oramed Pharmaceuticals Inc, sells Loxo Oncology Inc, NxStage Medical Inc, argenx SE, Ascendis Pharma A/S, Translate Bio Inc, Kura Oncology Inc, Incyte Corp, Concert Pharmaceuticals Inc, Immunomedics Inc, Valeritas Holdings Inc, Macrogenics Inc, Leap Therapeutics Inc, Advaxis Inc, Aptinyx Inc, Proteostasis Therapeutics Inc, Arcturus Therapeutics, Neos Therapeutics Inc during the 3-months ended 2019Q1, according to the most recent filings of the investment company, DAFNA Capital Management LLC. As of 2019Q1, DAFNA Capital Management LLC owns 72 stocks with a total value of $224 million. These are the details of the buys and sells.

For the details of DAFNA Capital Management LLC's stock buys and sells, go to https://www.gurufocus.com/guru/dafna+capital+management+llc/current-portfolio/portfolio

These are the top 5 holdings of DAFNA Capital Management LLC
  1. Stereotaxis Inc (STXS) - 13,680,554 shares, 11.90% of the total portfolio.
  2. Sage Therapeutics Inc (SAGE) - 123,806 shares, 8.79% of the total portfolio. Shares added by 18.69%
  3. Blueprint Medicines Corp (BPMC) - 119,718 shares, 4.28% of the total portfolio. Shares added by 29.16%
  4. AtriCure Inc (ATRC) - 318,729 shares, 3.81% of the total portfolio.
  5. Alder BioPharmaceuticals Inc (ALDR) - 571,013 shares, 3.48% of the total portfolio. Shares added by 44.19%
New Purchase: Mersana Therapeutics Inc (MRSN)

DAFNA Capital Management LLC initiated holding in Mersana Therapeutics Inc. The purchase prices were between $3.51 and $7.3, with an estimated average price of $5.02. The stock is now traded at around $6.00. The impact to a portfolio due to this purchase was 0.95%. The holding were 403,300 shares as of .

New Purchase: Genocea Biosciences Inc (GNCA)

DAFNA Capital Management LLC initiated holding in Genocea Biosciences Inc. The purchase prices were between $0.29 and $0.9, with an estimated average price of $0.61. The stock is now traded at around $0.72. The impact to a portfolio due to this purchase was 0.52%. The holding were 1,989,653 shares as of .

New Purchase: Inogen Inc (INGN)

DAFNA Capital Management LLC initiated holding in Inogen Inc. The purchase prices were between $90.12 and $152.23, with an estimated average price of $125.39. The stock is now traded at around $74.85. The impact to a portfolio due to this purchase was 0.42%. The holding were 9,900 shares as of .

New Purchase: Savara Inc (SVRA)

DAFNA Capital Management LLC initiated holding in Savara Inc. The purchase prices were between $6.71 and $8.6, with an estimated average price of $7.52. The stock is now traded at around $11.31. The impact to a portfolio due to this purchase was 0.36%. The holding were 110,275 shares as of .

New Purchase: Aileron Therapeutics Inc (ALRN)

DAFNA Capital Management LLC initiated holding in Aileron Therapeutics Inc. The purchase prices were between $0.84 and $2.2, with an estimated average price of $1.55. The stock is now traded at around $1.29. The impact to a portfolio due to this purchase was 0.09%. The holding were 99,502 shares as of .

Added: WAVE Life Sciences Ltd (WVE)

DAFNA Capital Management LLC added to a holding in WAVE Life Sciences Ltd by 297.82%. The purchase prices were between $32.69 and $47.91, with an estimated average price of $40.58. The stock is now traded at around $27.05. The impact to a portfolio due to this purchase was 2.47%. The holding were 190,554 shares as of .

Added: Alder BioPharmaceuticals Inc (ALDR)

DAFNA Capital Management LLC added to a holding in Alder BioPharmaceuticals Inc by 44.19%. The purchase prices were between $10.25 and $14.71, with an estimated average price of $12.94. The stock is now traded at around $10.95. The impact to a portfolio due to this purchase was 1.07%. The holding were 571,013 shares as of .

Added: Blueprint Medicines Corp (BPMC)

DAFNA Capital Management LLC added to a holding in Blueprint Medicines Corp by 29.16%. The purchase prices were between $48.7 and $86.6, with an estimated average price of $73.56. The stock is now traded at around $77.20. The impact to a portfolio due to this purchase was 0.97%. The holding were 119,718 shares as of .

Added: Kadmon Holdings Inc (KDMN)

DAFNA Capital Management LLC added to a holding in Kadmon Holdings Inc by 1056.00%. The purchase prices were between $2.08 and $2.99, with an estimated average price of $2.51. The stock is now traded at around $2.29. The impact to a portfolio due to this purchase was 0.81%. The holding were 757,177 shares as of .

Added: Cytokinetics Inc (CYTK)

DAFNA Capital Management LLC added to a holding in Cytokinetics Inc by 115.41%. The purchase prices were between $5.95 and $10.19, with an estimated average price of $7.34. The stock is now traded at around $10.68. The impact to a portfolio due to this purchase was 0.77%. The holding were 400,294 shares as of .

Added: Corbus Pharmaceuticals Holdings Inc (CRBP)

DAFNA Capital Management LLC added to a holding in Corbus Pharmaceuticals Holdings Inc by 96.77%. The purchase prices were between $5.76 and $8.95, with an estimated average price of $7.36. The stock is now traded at around $7.39. The impact to a portfolio due to this purchase was 0.47%. The holding were 305,000 shares as of .

Sold Out: Loxo Oncology Inc (LOXO)

DAFNA Capital Management LLC sold out a holding in Loxo Oncology Inc. The sale prices were between $131.02 and $234.75, with an estimated average price of $222.49.

Sold Out: NxStage Medical Inc (NXTM)

DAFNA Capital Management LLC sold out a holding in NxStage Medical Inc. The sale prices were between $28.24 and $30, with an estimated average price of $28.95.

Sold Out: Translate Bio Inc (TBIO)

DAFNA Capital Management LLC sold out a holding in Translate Bio Inc. The sale prices were between $4.9 and $10.23, with an estimated average price of $7.66.

Sold Out: Incyte Corp (INCY)

DAFNA Capital Management LLC sold out a holding in Incyte Corp. The sale prices were between $63.56 and $88.17, with an estimated average price of $81.08.

Sold Out: Concert Pharmaceuticals Inc (CNCE)

DAFNA Capital Management LLC sold out a holding in Concert Pharmaceuticals Inc. The sale prices were between $12.07 and $17.54, with an estimated average price of $14.7.

Sold Out: Valeritas Holdings Inc (VLRX)

DAFNA Capital Management LLC sold out a holding in Valeritas Holdings Inc. The sale prices were between $0.33 and $0.55, with an estimated average price of $0.4.



Here is the complete portfolio of DAFNA Capital Management LLC. Also check out:

1. DAFNA Capital Management LLC's Undervalued Stocks
2. DAFNA Capital Management LLC's Top Growth Companies, and
3. DAFNA Capital Management LLC's High Yield stocks
4. Stocks that DAFNA Capital Management LLC keeps buying

Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:


Performances of the stocks mentioned by insider


User Generated Screeners


pjmason14Momentum
pascal.van.garsseHigh FCF-M2
kosalmmuse6
kosalmmuseBest one1
DBrizanall 2019Feb26
kosalmmuseBest one
DBrizanall 2019Feb25
kosalmmuseNice
kosalmmusehan
MsDale*52-Week Low
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK